Rezolute (NASDAQ:RZLT) Upgraded to “Hold” at Zacks Research

Rezolute (NASDAQ:RZLT – Get Free Report) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks reports.

Several other research firms have also issued reports on RZLT. Craig Hallum raised shares of Rezolute from a “hold” rating to a “buy” rating and increased their target price for the stock from $4.00 to $7.00 in a research note on Tuesday, September 29th. Citizens Jmp upped their price target on Rezolute from $11.00 to $15.00 and gave the stock a “market outperform” rating in a report on Tuesday, October 6th. HC Wainwright upped their target price on Rezolute from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, September 25th. Lake Street Capital increased their target price on Rezolute from $9.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, October 6th. Finally, Cantor Fitzgerald raised shares of Rezolute from a “neutral” rating to an “overweight” rating in a research note on Monday, October 5th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Rezolute currently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Check Out Our Latest Report on Rezolute

Rezolute Stock Performance

Rezolute stock opened at $4.20 on Wednesday. Rezolute has a 12 month low of $1.07 and a 12 month high of $11.16. The stock’s 50 day simple moving average is $4.05 and its two-hundred day simple moving average is $3.94.

Rezolute (NASDAQ:RZLT – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. As a group, equities research analysts expect that Rezolute will post -0.66 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. AlphaCentric Advisors LLC increased its holdings in shares of Rezolute by 4.5% in the third quarter. AlphaCentric Advisors LLC now owns 75,495 shares of the company’s stock valued at $313,000 after purchasing an additional 3,240 shares during the last quarter. Auxano Advisors LLC purchased a new stake in Rezolute in the 2nd quarter valued at about $52,000. Sequoia Financial Advisors LLC acquired a new position in Rezolute during the second quarter worth $75,000. WINTON GROUP Ltd acquired a new position in Rezolute during the 2nd quarter worth about $88,000. Finally, ADAR1 Capital Management LLC increased its stake in Rezolute by 51.7% during the 1st quarter. ADAR1 Capital Management LLC now owns 58,679 shares of the company’s stock worth $179,000 after buying an additional 20,000 shares during the period. 82.97% of the stock is owned by hedge funds and other institutional investors.

About Rezolute

(Get Free Report)

Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company’s lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia.

Further Reading

Analyst Recommendations for Rezolute (NASDAQ:RZLT)

Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.